The Psychedelic Money Graveyard: Renames, Reverse Mergers, and the Companies That Didn't Make It
Part two of the funding series. Behind the rankings is a much messier story — a wave of renames, a wave of consolidation, and a genuine graveyard of companies that raised real money and still didn't survive.
The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments
We tracked every public company, private funding round, and government dollar we could verify in the psychedelic-therapeutics sector. Part one is the rankings. Part two, next Friday, is the trends, the mergers, and the graveyard.
Ibogaine's Flagship Drug Hit a Cardiac Signal and a Lawsuit. A Different Drug Is Now Leading.
A company-by-company look at who holds ibogaine's 53 patents — and how the compound's original opioid-use-disorder program stalled over a cardiac safety signal and litigation, while a different drug, for a different disease, became the first ibogaine-class compound ever cleared for a US trial.
Ketamine Has More Patents Than Any Compound We Track. So Why Isn't Big Pharma More Interested?
Ketamine holds 71 granted patents in our tracker — more than psilocybin, more than MDMA, more than anything else. Almost all of them trace to one drug. Here's why the compound with the biggest head start isn't getting the psychedelic industry's gold-rush treatment.
Altitude Intelligence Brief: Who's Actually Making Money on Depression, Anxiety, and PTSD
The drugs most Americans take for depression, anxiety, and PTSD are decades-old generics that make pharma almost nothing. The real money is in five newer, still-patented drugs most patients have never heard of.
Psychedelics in Uniform: What the Military Did to Soldiers, and What the VA Is Now Asking of Veterans
The Army spent decades dosing enlisted men with psychedelics they weren't told they were taking. Eighty years later, the VA and Pentagon are running versions of the same experiment again — with consent forms, IRBs, and an executive order behind them.
LSD Has 14 Patents in Our Tracker. The Company Closest to Approval Owns One.
A company-by-company look at the smallest patent footprint of any compound on our tracker — and why Definium, the company furthest along in trials, barely shows up in it.
The 5-MeO-DMT Patent Race Has a Twist: The Clinical Leader Barely Owns Any of It
A company-by-company look at who holds 5-MeO-DMT''s 164 patents — and why the program with the strongest Phase 2b data in the field has almost none of them.
Psilocybin Has 223 Patents in Play. Here's Who Actually Holds Them.
A company-by-company look at who's patenting psilocybin, what they're actually claiming, and why one of the biggest names in the field has spent a year fighting to keep its patents alive.
677 Patents and One FDA Rejection: Mapping the Psychedelic Drug Pipeline
Our own count of who's filing patents on psilocybin, MDMA, LSD, ketamine, ibogaine, and 5-MeO-DMT — what they're claiming to treat, where they're based, and the one company that's already been told no by the FDA.
Clinical vs. Consumer: Navigating the New Psilocybin Landscape
The same compound, very different experiences. Understanding the difference between clinical and consumer use is essential.